Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.

[1]  R. Labianca,et al.  Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  R. Labianca,et al.  Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. , 2014 .

[3]  Wei-Guo Zhu,et al.  A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  Y. Bang,et al.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial , 2012, The Lancet.

[5]  Joon-Oh Park,et al.  Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Y. Ohashi,et al.  Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Labianca,et al.  The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  F. D. De Braud,et al.  Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Inoue,et al.  Gastric Cancer Working Group report. , 2010, Japanese journal of clinical oncology.

[10]  D. Sargent,et al.  Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. , 2010, JAMA.

[11]  H. Putter,et al.  Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. , 2010, The Lancet. Oncology.

[12]  D. Cunningham,et al.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  W. Scheithauer,et al.  Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Yasuo Ohashi,et al.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.

[15]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[16]  Jen-Hao Chen,et al.  Nodal dissection for patients with gastric cancer: a randomised controlled trial. , 2006, The Lancet. Oncology.

[17]  M. Bains,et al.  Patterns of Initial Recurrence in Completely Resected Gastric Adenocarcinoma , 2004, Annals of surgery.

[18]  S. Lo,et al.  Incidence and Factors Associated with Recurrence Patterns after Intended Curative Surgery for Gastric Cancer , 2003, World Journal of Surgery.

[19]  W. Allum,et al.  Guidelines for the management of oesophageal and gastric cancer , 2002, Gut.

[20]  Aller,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2002, The New England journal of medicine.

[21]  Y. Kodera,et al.  The number of metastatic lymph nodes: a promising prognostic determinant for gastric carcinoma in the latest edition of the TNM classification. , 1998, Journal of the American College of Surgeons.

[22]  Y. Maehara,et al.  Prognostic significance of the number of positive lymph nodes in gastric carcinoma , 1994, The British journal of surgery.